Full Text View
Tabular View
No Study Results Posted
Related Studies
Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colon Cancer (PERIOP-01)
This study is currently recruiting participants.
Verified November 2012 by Ottawa Hospital Research Institute
Study NCT01455831   Information provided by Ottawa Hospital Research Institute

First Received on October 18, 2011.   Last Updated on November 1, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Adenocarcinoma of the Colon
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Colonic Neoplasms
More general conditions related to this trial
Carcinoma
Colonic Diseases
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Tinzaparin
Additional drug interventions recognized in this trial
Dalteparin
Heparin, Low-Molecular-Weight
More general drug interventions related to this trial
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Ottawa Hospital Research Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services